Kroll David S, Nieva Harry Reyes, Barsky Arthur J, Linder Jeffrey A
Harvard Medical School, Boston, MA, USA.
Department of Psychiatry, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02120, USA.
J Gen Intern Med. 2016 Sep;31(9):1027-34. doi: 10.1007/s11606-016-3740-0. Epub 2016 May 13.
Benzodiazepine use is associated with adverse drug events and higher mortality. Known risk factors for benzodiazepine-related adverse events include lung disease, substance use, and vulnerability to fracture.
To determine whether benzodiazepine prescribing is associated with risk factors for adverse outcomes.
Longitudinal cohort study between July 1, 2011, and June 30, 2012.
Patients who visited hospital- and community-based practices in a primary care practice-based research network.
Odds ratio of having a target medical diagnosis for patients who received standard and high-dose benzodiazepine prescriptions; rates per 100 patients for outpatient and emergency department visits and hospitalizations.
Among 65,912 patients, clinicians prescribed at least one benzodiazepine to 15 % (9821). Of benzodiazepine recipients, 5 % received high doses. Compared to non-recipients, benzodiazepine recipients were more likely to have diagnoses of depression (OR, 2.7; 95 % CI, 2.6-2.9), substance abuse (OR, 2.2; 95 % CI, 1.9-2.5), tobacco use (OR, 1.7; 95 % CI, 1.5-1.8), osteoporosis (OR, 1.6; 95 % CI, 1.5-1.7), chronic obstructive pulmonary disease (OR, 1.6; 95 % CI, 1.5-1.7), alcohol abuse (OR, 1.5; 95 % CI, 1.3-1.7), sleep apnea (OR, 1.5; 95 % CI, 1.3-1.6), and asthma (OR, 1.5; 95 % CI, 1.4-1.5). Compared to low-dose benzodiazepine recipients, high-dose benzodiazepine recipients were even more likely to have certain medical diagnoses: substance abuse (OR, 7.5; 95 % CI, 5.5-10.1), alcohol abuse (OR, 3.2; 95 % CI, 2.2-4.5), tobacco use (OR, 2.7; 95 % CI, 2.1-3.5), and chronic obstructive pulmonary disease (OR, 1.5; 95 % CI, 1.2-1.9). Benzodiazepine recipients had more primary care visits per 100 patients (408 vs. 323), specialist outpatient visits (815 vs. 578), emergency department visits (47 vs. 29), and hospitalizations (26 vs. 15; p < .001 for all comparisons).
Clinicians prescribed benzodiazepines and high-dose benzodiazepines more frequently to patients at higher risk for benzodiazepine-related adverse events. Benzodiazepine prescribing was associated with increased healthcare utilization.
使用苯二氮䓬类药物与药物不良事件及更高的死亡率相关。已知的与苯二氮䓬类药物相关不良事件的风险因素包括肺部疾病、物质使用和骨折易感性。
确定开具苯二氮䓬类药物处方是否与不良结局的风险因素相关。
2011年7月1日至2012年6月30日的纵向队列研究。
在基于初级保健实践的研究网络中就诊于医院和社区医疗机构的患者。
接受标准剂量和高剂量苯二氮䓬类药物处方的患者患有目标医学诊断的比值比;每100名患者的门诊、急诊科就诊和住院率。
在65912名患者中,临床医生给15%(9821名)患者开具了至少一种苯二氮䓬类药物。在苯二氮䓬类药物接受者中,5%接受了高剂量药物。与未接受者相比,苯二氮䓬类药物接受者更有可能被诊断为抑郁症(比值比,2.7;95%置信区间,2.6 - 2.9)、物质滥用(比值比,2.2;95%置信区间,1.9 - 2.5)、吸烟(比值比,1.7;95%置信区间,1.5 - 1.8)、骨质疏松症(比值比,1.6;95%置信区间,1.5 - 1.7)、慢性阻塞性肺疾病(比值比,1.6;95%置信区间,1.5 - 1.7)、酒精滥用(比值比,1.5;95%置信区间,1.3 - 1.7)、睡眠呼吸暂停(比值比,1.5;95%置信区间,1.3 - 1.6)和哮喘(比值比,1.5;95%置信区间,1.4 - 1.5)。与低剂量苯二氮䓬类药物接受者相比,高剂量苯二氮䓬类药物接受者更有可能患有某些医学诊断:物质滥用(比值比,7.5;95%置信区间,5.5 - 10.1)、酒精滥用(比值比,3.2;95%置信区间,2.2 - 4.5)、吸烟(比值比,2.7;95%置信区间,2.1 - 3.5)和慢性阻塞性肺疾病(比值比,1.5;95%置信区间,1.2 - 1.9)。每100名患者中,苯二氮䓬类药物接受者的初级保健就诊次数更多(408次对323次)、专科门诊就诊次数更多(815次对578次)、急诊科就诊次数更多(47次对29次)以及住院次数更多(26次对15次;所有比较的p值均<0.001)。
临床医生更频繁地给发生苯二氮䓬类药物相关不良事件风险较高的患者开具苯二氮䓬类药物和高剂量苯二氮䓬类药物。开具苯二氮䓬类药物处方与医疗保健利用率增加相关。